Catalog No.
Product Name
Application
Product Information
Citations
-
SREBP inhibitor
PF 429242 is a reversible, competitive inhibitor of sterol regulatory element-binding protein (SREBP) site 1 protease.- Ziqing Yan, .et al. , Am J Physiol Cell Physiol, 2024, Jun 1;326(6):C1683-C1696 PMID: 38646785
- Kai Xue, .et al. , Oxid Med Cell Longev, 2021, Nov 26;2021:5710440 PMID: 34873430
- Tong-bing Wang, .et al. , Cell Death Dis, 2021, Aug; 12(8): 717 PMID: 34285190
- Shiying Xie, .et al. , Am J Physiol Renal Physiol, 2020, Aug 31 PMID: 32865015
- Yang PM, .et al. , Am J Cancer Res, 2019, Oct 1;9(10):2120-2139 PMID: 31720078
- Hui Fang, .et al. , Am J Physiol Cell Physiol, 2017, Dec 1; 313(6): C632-C643 PMID: 28903918
- Tsutomu Nakagawa, .et al. , J Biochem, 2016, Apr 1;161(4):369-379 PMID: 28013223
- Shimada S, .et al. , Virology, 2015, Aug;482:19-27 PMID: 25817401
- Jan H. Reiling, .et al. , Nat Cell Biol., 2013, 15(12): 1473-1485 PMID: 24185178
-
SREBP inhibitor
Fatostatin Hydrobromide is an inhibitor of sterol regulatory element-binding protein (SREBP). -
SREBP inhibitor
Nicodicosapent is a fatty acid niacin conjugate that is also an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1. -
SREBP activation inhibitor
Fatostatin (125B11), a specific inhibitor of SREBP activation, impairs the activation of SREBP-1 and SREBP-2. -
SREBPs/microRNA 33a/b Inhibitor
Pseudoprotodioscin is a furostanoside that inhibits Sterol Regulatory Element-Binding Proteins (SREBPs) and microRNA 33a/b. This inhibition leads to a reduction in the gene expression involved in cholesterol and triglyceride synthesis. Pseudoprotodioscin is valuable for research on lipid metabolism and related cardiovascular diseases. -
SREBP Maturation Inhibitor
4'-Hydroxyflavanone is an inhibitor of SREBP maturation, impacting lipid synthesis. As a synthetic analogue of flavanone, it demonstrates potential in studies related to hepatic steatosis and dyslipidemia. This compound can be utilized to explore mechanisms of lipid metabolism and associated disorders. -
SREBP/SCAP Inhibitor
SREBP/SCAP-IN-1 is a selective inhibitor of the SREBP/SCAP complex, which plays a crucial role in lipid metabolism and cellular cholesterol homeostasis. This compound effectively disrupts the signaling pathway involved in sterol regulatory element-binding protein activation, providing insight into lipid regulation mechanisms. Research applications include investigating metabolic disorders, cardiovascular diseases, and potential therapeutic strategies targeting cholesterol metabolism. -
SREBP/SCAP Inhibitor
SREBP/SCAP-IN-2 is a selective inhibitor of the SREBP/SCAP complex, which plays a crucial role in lipid metabolism and cellular cholesterol homeostasis. This compound effectively interferes with the activation and function of SREBP, thereby modulating lipid biosynthesis pathways. SREBP/SCAP-IN-2 is valuable for research focusing on metabolic disorders, obesity, and cardiovascular diseases, providing insights into the regulatory mechanisms of lipid metabolism.
